From Linda M Rio, PWN contributor and mental health professional – I’m often contacted by those with an already diagnosed pituitary disorder or those who are searching for help and suspect they are impacted but
In today’s podcast, Dr. Lewis Blevins dives into the fascinating findings from a study by Corcept Therapeutics on the prevalence of hypercortisolism in people with type 2 diabetes.
This is a very informative discussion about the new indications of the Cushing’s Drug Isturisa® (osilodrostat) with Dr. Mario Maldonado, who heads global development for endocrinology at Recordati Rare Diseases.
There is growing interest in the use of cortisol pumps to treat patients with adrenal insufficiency, though most physicians in the US lack experience in this area. Dr. Lewis Blevins caught up with Dr. Naila Goldenberg at The Endocrine Society Meeting in San Francisco, California, in July 2025.
Dr. Lewis Blevins caught up with Dr. Francesca Galbiati at The Endocrine Society Meeting in San Francisco, California in July 2025. In this video she reviews her work relating to the effects of intranasal oxytocin on sex steroid levels in obese patients.
Dr. Lewis Blevins talks with Dr. Iacopo Chiodini at The Endocrine Society Meeting in San Francisco, California to discuss his presentation illustrating the benefits of adrenalectomy in patients with MACS. In this video, capturing the presentation of data, they also discuss the need for studies to address the medical management of patients with MACS.
Numerous studies have suggested that hypercortisolism is present in 3-8 percent of unselected patients with type 2 diabetes mellitus. Recent data from the Catalyst study suggest that hypercortisolism may be seen in as many as one-quarter of patients with uncontrolled type 2 diabetes…
The Evolution of our Understanding of the Nuances of Pathologic Cortisol Secretion. A few highlights: Cushing syndrome refers to the classical appearance of hypercortisolism as described by Dr. Harvey Cushing. Many patients with hypercortisolism or
I recently had the pleasure of meeting Camurus CEO Fredrik Tiberg. We initially connected on a Zoom call and later met at the European Endocrine Conference held in Copenhagen, Denmark in May. We agreed to meet in person, learn more about the company and record a podcast.
In today’s podcast, Dr. Lewis Blevins discusses relacorilant, a drug currently in development by Corcept Therapeutics for the treatment of hypercortisolism. Clinical trials to date have shown encouraging results, with improvements in blood pressure, glucose control, weight, and body composition.